195 related articles for article (PubMed ID: 37386877)
21. How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases.
Cervetti G; Ghio F; Cecconi N; Morganti R; Galimberti S; Petrini M
J Chemother; 2017 Apr; 29(2):126-129. PubMed ID: 27454143
[TBL] [Abstract][Full Text] [Related]
22. Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?
Kalpadakis C; Pangalis GA; Vassilakopoulos TP; Sachanas S; Angelopoulou MK
Leuk Lymphoma; 2014 Jul; 55(7):1463-70. PubMed ID: 24050506
[TBL] [Abstract][Full Text] [Related]
23. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.
Else M; Marín-Niebla A; de la Cruz F; Batty P; Ríos E; Dearden CE; Catovsky D; Matutes E
Br J Haematol; 2012 Nov; 159(3):322-8. PubMed ID: 23016878
[TBL] [Abstract][Full Text] [Related]
24. Splenic Marginal Zone Lymphoma with Acquired von Willebrand Syndrome Diagnosed via Splenic Bleeding.
Komeno Y; Shibuya N; Uryu H; Yamada H; Toda T; Shibasaki M; Kunishima S; Iihara K; Ryu T
Intern Med; 2017; 56(5):557-562. PubMed ID: 28250305
[TBL] [Abstract][Full Text] [Related]
25. Laparoscopic splenectomy for treatment of splenic marginal zone lymphoma.
Wu Z; Zhou J; Wang X; Li YB; Niu T; Peng B
World J Gastroenterol; 2013 Jun; 19(24):3854-60. PubMed ID: 23840125
[TBL] [Abstract][Full Text] [Related]
26. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab.
Kalpadakis C; Pangalis GA; Sachanas S; Rontogianni D; Korkolopoulou P; Milionis V; Vassilakopoulos TP; Papadaki HA; Angelopoulou MK
Leuk Lymphoma; 2016 Nov; 57(11):2705-8. PubMed ID: 27082039
[No Abstract] [Full Text] [Related]
27. Splenic marginal zone lymphoma: disease features and management.
Matutes E
Expert Rev Hematol; 2013 Dec; 6(6):735-45. PubMed ID: 24168526
[TBL] [Abstract][Full Text] [Related]
28. Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation.
Bastidas-Mora G; Beà S; Navarro A; Gine E; Costa D; Delgado J; Baumann T; Magnano L; Rivas-Delgado A; Villamor N; Colomer D; Lopez-Guerra M; Rozman M; Balagué O; Martínez D; Baptista MJ; Escoda L; Alcoceba M; Blanes M; Climent F; Campo E; Wotherspoon A; López-Guillermo A; Matutes E
Br J Haematol; 2022 Jan; 196(1):146-155. PubMed ID: 34519021
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological features of splenic tumours of lymphoid tissue.
Chen DB; Shen DH; Yang SM; Fang XZ
Pathol Res Pract; 2018 Dec; 214(12):1952-1958. PubMed ID: 30087035
[TBL] [Abstract][Full Text] [Related]
30. Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
Mulas O; Caocci G; Dessì D; Mantovani D; Moi G; Cabras MG; La Nasa G
Acta Haematol; 2021; 144(3):322-326. PubMed ID: 32892194
[TBL] [Abstract][Full Text] [Related]
31. Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma.
Lyu R; Wang T; Wang Y; Xiong W; Wang H; Yan Y; Wang Q; Liu W; An G; Huang W; Sui W; Xu Y; Zou D; Wang J; Qiu L; Yi S
Br J Haematol; 2021 Sep; 194(5):862-869. PubMed ID: 34328213
[TBL] [Abstract][Full Text] [Related]
32. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.
Xing KH; Kahlon A; Skinnider BF; Connors JM; Gascoyne RD; Sehn LH; Savage KJ; Slack GW; Shenkier TN; Klasa R; Gerrie AS; Villa D
Br J Haematol; 2015 May; 169(4):520-7. PubMed ID: 25854936
[TBL] [Abstract][Full Text] [Related]
33. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
34. Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma.
Gebhart J; Lechner K; Skrabs C; Sliwa T; Müldür E; Ludwig H; Nösslinger T; Vanura K; Stamatopoulos K; Simonitsch-Klupp I; Chott A; Quehenberger P; Mitterbauer-Hohendanner G; Pabinger I; Jäger U; Geissler K
Thromb Res; 2014 Nov; 134(5):980-4. PubMed ID: 25201005
[TBL] [Abstract][Full Text] [Related]
35. [Successful treatment with rituximab in a patient with splenic marginal zone B-cell lymphoma accompanied by cold agglutinin disease].
Yasuyama M; Kawauchi K; Otsuka K; Tamura H; Fujibayashi M
Nihon Ronen Igakkai Zasshi; 2014; 51(6):569-75. PubMed ID: 25749330
[TBL] [Abstract][Full Text] [Related]
36. Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma.
Philip AZ
J Natl Compr Canc Netw; 2018 Mar; 16(3):230-233. PubMed ID: 29523661
[TBL] [Abstract][Full Text] [Related]
37. Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden.
Sima A; Hollander P; Baecklund E; Smedby KE; Enblad G; Amini RM
Br J Haematol; 2021 Aug; 194(3):568-579. PubMed ID: 34109612
[TBL] [Abstract][Full Text] [Related]
38. Rituximab monotherapy for splenic marginal zone lymphoma with villous lymphocytes: report on long-term disease control for two patients with recurrence after splenectomy.
Debiasi M; Hehnemann M; Garicochea B
Sao Paulo Med J; 2010 Dec; 128(6):375-7. PubMed ID: 21308163
[TBL] [Abstract][Full Text] [Related]
39. Splenectomy in Lymphoproliferative Disorders: A Single Eastern European Center Experience.
Onisâi M; Vlădăreanu AM; Nica A; Spînu A; Găman M; Bumbea H; Voican I; Iordan I; Alexandru A; Zdrenghea M; Gheorghita D; Grădinaru S
Medicina (Kaunas); 2019 Dec; 56(1):. PubMed ID: 31892196
[No Abstract] [Full Text] [Related]
40. Splenic marginal zone lymphoma: A US population-based survival analysis (1999-2016).
Florindez JA; Alderuccio JP; Reis IM; Lossos IS
Cancer; 2020 Nov; 126(21):4706-4716. PubMed ID: 32767702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
